ArticleProceedings of the National Academy of Sciences of the United States of America2016
Directed vaccination against pneumococcal disease.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- ZPY-CpG-Ch, a broad coverage vaccine againstScience advances · 2026Article
- Glycoconjugate vaccines: platforms and adjuvants for directed immunity.Glycobiology · 2024Review
- Immunization with recombinantExperimental biology and medicine (Maywood, N.J.) · 2024Article
- Prophylactic vaccine delivery systems against epidemic infectious diseases.Advanced drug delivery reviews · 2021Review
- Immunobiology of Carbohydrates: Implications for Novel Vaccine and Adjuvant Design Against Infectious Diseases.Frontiers in cellular and infection microbiology · 2021Review
- Pneumococcal Extracellular Serine Proteases: Molecular Analysis and Impact on Colonization and Disease.Frontiers in cellular and infection microbiology · 2021Review
- The serine protease HtrA plays a key role in heat-induced dispersal of pneumococcal biofilms.Scientific reports · 2020Article
- Extended Polysaccharide Analysis within the Liposomal Encapsulation of Polysaccharides System.Materials (Basel, Switzerland) · 2020Article
- Extracellular Pneumococcal Serine Proteases Affect Nasopharyngeal Colonization.Frontiers in cellular and infection microbiology · 2020Article
- Opening the OPK Assay Gatekeeper: Harnessing Multi-Modal Protection by Pneumococcal Vaccines.Pathogens (Basel, Switzerland) · 2019Article
- Antigen delivery format variation and formulation stability through use of a hybrid vector.Vaccine: X · 2019Article
- Metalloporphyrin Nanoparticles: Coordinating Diverse Theranostic Functions.Coordination chemistry reviews · 2019Article
- Evolving concepts in bone infection: redefining "biofilm", "acute vs. chronic osteomyelitis", "the immune proteome" and "local antibiotic therapy".Bone research · 2019Review
- Serotype-Independent Protection Against Invasive Pneumococcal Infections Conferred by Live Vaccine WithFrontiers in immunology · 2019Article
- Engineering a Next-Generation Glycoconjugate-Like Streptococcus pneumoniae Vaccine.ACS infectious diseases · 2018Article
- Standardization of Pneumococcal Biofilm Release to PncO Expression, a Predictive Measurement of Virulence.Infection and immunity · 2018Article
- Phenotypic Variation during Biofilm Formation: Implications for Anti-Biofilm Therapeutic Design.Materials (Basel, Switzerland) · 2018Review
- Bacterial-Host Interactions: Physiology and Pathophysiology of Respiratory Infection.Physiological reviews · 2018Review
- Changing Priorities in Vaccinology: Antibiotic Resistance Moving to the Top.Frontiers in immunology · 2018Review
- Antibodies Reactive to CommensalFrontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Immunization strategies against commensal bacterial pathogens have long focused on eradicating asymptomatic carriage as well as disease, resulting in changes in the colonizing microflora with unknown future consequences. Additionally, current vaccines are not easily adaptable to sequence diversity and immune evasion. Here, we present a "smart" vaccine that leverages our current understanding of disease transition from bacterial carriage to infection with the pneumococcus serving as a model organism. Using conserved surface proteins highly expressed during virulent transition, the vaccine mounts an immune response specifically against disease-causing bacterial populations without affecting carriage. Aided by a delivery technology capable of multivalent surface display, which can be adapted easily to a changing clinical picture, results include complete protection against the development of pneumonia and sepsis during animal challenge experiments with multiple, highly variable, and clinically relevant pneumococcal isolates. The approach thus offers a unique and dynamic treatment option readily adaptable to other commensal pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.